Cari­bou aces its first round of hu­man da­ta in search of an off-the-shelf CAR-T break­through

Cari­bou Bio­sciences just flipped its first card on hu­man da­ta for its lead off-the-shelf an­ti-CD19 CAR-T, and it’s an ace.

The biotech re­port­ed out on a tiny group of pa­tients — just five treat­ment-re­sis­tant in­di­vid­u­als suf­fer­ing from B cell non-Hodgkin’s lym­phoma in this first round — and came up with a 100% over­all re­sponse rate with an 80% com­plete re­sponse rate.

Those head­line num­bers quick­ly reg­is­tered as a rare win these days in the bleak biotech sec­tor, as Cari­bou’s share price $CR­BU surged 25%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER